Free tool
FAERS Monitor: Coreg
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020297 or its brand name (Coreg, Carvedilol). Reports on generic versions are filed under their own applications.
Reports
136,140
Serious
94,757
70% of reports
Hospitalization
54,899
Death reported
16,459
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue9,046
- dyspnoea8,485
- diarrhoea7,248
- dizziness7,052
- nausea6,781
- drug ineffective5,941
- death5,882
- hypotension5,755
- asthenia5,512
- off label use4,744
- acute kidney injury4,527
- fall4,508
- pain4,504
- cardiac failure congestive4,463
- headache4,451
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 1,227 |
| 2005 | 1,652 |
| 2006 | 2,062 |
| 2007 | 2,497 |
| 2008 | 2,214 |
| 2009 | 2,734 |
| 2010 | 3,387 |
| 2011 | 4,256 |
| 2012 | 4,744 |
| 2013 | 4,238 |
| 2014 | 7,329 |
| 2015 | 8,726 |
| 2016 | 10,195 |
| 2017 | 9,778 |
| 2018 | 10,884 |
| 2019 | 10,340 |
| 2020 | 8,835 |
| 2021 | 8,114 |
| 2022 | 7,236 |
| 2023 | 7,051 |
| 2024 | 6,870 |
| 2025 | 6,725 |
| 2026 | 5,045 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,918,019 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| cardiac failure congestiveSignal | 4,463 | 9.0 | 8.8 | 30,202 |
| acute kidney injurySignal | 4,527 | 4.7 | 4.5 | 12,798 |
| hypotensionSignal | 5,755 | 4.5 | 4.4 | 15,541 |
| dyspnoeaSignal | 8,485 | 2.3 | 2.3 | 6,559 |
| astheniaSignal | 5,512 | 2.3 | 2.2 | 3,989 |
| dizzinessSignal | 7,052 | 2.2 | 2.2 | 4,668 |
| fallSignal | 4,508 | 2.1 | 2.0 | 2,629 |
| fatigue | 9,046 | 1.8 | 1.8 | 3,329 |
| diarrhoea | 7,248 | 1.7 | 1.7 | 2,341 |
| nausea | 6,781 | 1.3 | 1.3 | 561 |
| pain | 4,504 | 1.1 | 1.1 | 73 |
| headache | 4,451 | 1.1 | 1.1 | 39 |
| death | 5,882 | 1.1 | 1.0 | 18 |
| off label use | 4,744 | 0.8 | 0.8 | 158 |
| drug ineffective | 5,941 | 0.7 | 0.7 | 844 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.